Blog

For years, pomegranates have enjoyed a reputation as a “heart-healthy” fruit. As a cardiovascular researcher, I have often been asked a seemingly simple question: If pomegranates are so good for us, how exactly do they work? Our recent study, published in Antioxidants, set out to answer that question—not by focusing on the fruit itself, but by following what happens after the body and, crucially, the gut microbiome gets involved.

Atherosclerosis—an inflammatory disease that underlies heart attacks and strokes—develops slowly. It begins when low-density lipoprotein (LDL) particles become trapped and oxidized in artery walls, triggering immune cell recruitment, chronic inflammation, and eventually plaque formation. Drugs such as statins are effective but not perfect; many patients continue to carry significant “residual risk.” This has driven interest in other preventative and therapeutic agents. These include nutraceuticals—bioactive food components that may potentially complement existing therapies.

Among these, pomegranate polyphenols, especially a compound called punicalagin, have stood out. But there is a catch. Punicalagin itself is poorly absorbed. What actually enters the bloodstream in meaningful amounts are urolithins: small molecules made when the gut bacteria metabolize punicalagin and its breakdown product, ellagic acid.